Actively Recruiting
Autistic Symptomatology and Sensory Profile in Children With Prader-Willi Syndrome
Led by University Hospital, Toulouse · Updated on 2025-05-08
75
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Prader-Willi Syndrome (PWS) is a rare genetic neurodevelopmental disorder caused by damage in the 15q11-q13 region leading to hypothalamic dysfunction. People with PWS often show challenges in social interaction, intellectual difficulties, serious eating disorders, mood problems, and sensory features linked to autism. The CASSPER study investigates the unique autistic and sensory profiles in children with PWS and examines how early treatment with oxytocin might affect these symptoms, addressing the need for early and personalized care in this population. Children aged 3 to 16 years with genetically confirmed PWS participate in this observational study. They will undergo psychological and sensory tests, including questionnaires and sensory evaluations. The study focuses on assessing autistic symptoms, sensory profiles, cognitive-behavioral disorders, and the impact of early oxytocin treatment in younger children. These assessments take place during planned hospital visits or multidisciplinary consultations at the study centers. Participants will be evaluated over a short period, from day 1 to day 3, with researchers measuring autistic symptom prevalence, sensory characteristics, and their relationship with behavioral disorders and family quality of life. The study also compares these factors in children treated early with oxytocin versus those untreated. This approach aims to improve understanding of autistic traits in genetic neurodevelopmental disorders and support better care strategies for children with PWS.
CONDITIONS
Brief Title
Autistic Symptomatology and Sensory Profile in Children With Prader-Willi Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Child with genetically confirmed Prader-Willi Syndrome and identification of genetic subtype
- Child aged between 3 and 16 years
- Planned hospitalisation or multidisciplinary consultation for routine follow-up at an investigating centre
- No parental or legal guardian objection
You will not qualify if you...
- Change in psychotropic treatment (start, dose change, or stop) in the past 3 months
- Inability to provide clear information to parents or legal guardian
- Not covered by social security
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 days
Participants complete psychological questionnaires and sensorial tests to assess autistic symptomatology and sensory profile.
1 to 3 visits depending on assessments
Duration - Up to study completion in October 2026
Participants are monitored to understand the variability of symptoms and impact on family burden and quality of life.
Visits aligned with routine hospitalisation or multidisciplinary consultation
Trial Site Locations
Total: 1 location
1
Children Hospital
Toulouse, France
Actively Recruiting
Research Team
N
Nadege ALGANS
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here